
Alique Topalian: The biomarker bill has been reintroduced for the third time
Alique Topalian, Research Scientist of Survivorship and Supportive Services at University of Cincinnati Cancer Center, shared a post on LinkedIn:
“The biomarker bill (Ohio HB 8) has been reintroduced for the third time.
Watch my interview with Spectrum News about the importance of this bill. Biomarker testing can save lives, provide better health outcomes, improve quality of life, and reduce healthcare costs. 60% of oncology drugs developed in the last 5 years require or recommend biomarker testing prior to use.
Further – 66% of providers say insurance coverage is a barrier to appropriate biomarker testing for their patients. Health equity starts with access to care.
Thank you American Cancer Society Cancer Action Network (ACS CAN) for your constant efforts to improve the lives of patients.”
More posts featuring Alique Topalian.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023